Bolt Biotherapeutics
BOLT
29 hedge funds and large institutions have $7.33M invested in Bolt Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.05% less ownership
Funds ownership: 2.44% → 2.39% (-0.05%)
22% less funds holding
Funds holding: 37 → 29 (-8)
27% less capital invested
Capital invested by funds: $9.99M → $7.33M (-$2.66M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21.8K |
| 3 |
Squarepoint
New York
|
+$16.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$42.3K |
| 3 |
EGM
Engineers Gate Manager
New York
|
-$38.7K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$32.2K |
| 5 |
Goldman Sachs
New York
|
-$26.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $362 | -$10 | -1 | -2% |
|
|
SS
27
SBI Securities
Tokyo,
Japan
| $80 | – | – | – |
|
28
Barclays
London,
United Kingdom
| $56 | – | – | – |
|
|
SIC
29
Salem Investment Counselors
Winston Salem,
North Carolina
| $16 | – | – | – |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$42.3K | -3,948 | Closed |
|
|
EGM
31
Engineers Gate Manager
New York
| – | -$38.7K | -3,620 | Closed |
|
|
BCM
32
Bridgeway Capital Management
Houston,
Texas
| – | -$32.2K | -3,010 | Closed |
|
|
33
Goldman Sachs
New York
| – | -$26.8K | -2,501 | Closed |
|
|
VCIM
34
Velan Capital Investment Management
Alpharetta,
Georgia
| – | -$26.8K | -2,500 | Closed |
|
35
Millennium Management
New York
| – | -$25.2K | -2,351 | Closed |
|
36
Jane Street
New York
| – | -$22.4K | -2,093 | Closed |
|
|
VF
37
Virtu Financial
New York
| – | -$16K | -1,478 | Closed |
|
38
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$11.1K | -1,039 | Closed |
|
39
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.27K | -118 | Closed |
|
BOLT Hedge Fund Activity: Q1 2025 in Review
29 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2025, worth a combined $7.33M — down 27% from $9.99M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BOLT and 2 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $49.2K. The largest seller was Fidelity Investments, cutting an estimated $58.2K.
- 29 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2025, down from 37 in Q4 2024.
- Funds reported $7.33M of Bolt Biotherapeutics stock for Q1 2025, down 27% quarter-over-quarter.
- 2 funds opened new Bolt Biotherapeutics positions in Q1 2025 and 10 closed out, a net change of -8 holders.
- The largest Bolt Biotherapeutics buyer in Q1 2025 was Vanguard Group, an estimated $49.2K added.
- The largest Bolt Biotherapeutics seller in Q1 2025 was Fidelity Investments, an estimated $58.2K sold.
Based on aggregated 13F filings for Q1 2025.